News Releases

News Releases

Date Title
May 26, 2020 Sesen Bio to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare
May 11, 2020 Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability
Manufacturing and release testing of the Fujifilm pre-PPQ batch completed successfully Positive Interactions with EMA on Regulatory Pathway for Vicinium ® in Europe Market research conducted in 1Q 2020 supports Urologists prefer Vicinium to Keytruda ® CAMBRIDGE, Mass.
May 7, 2020 Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium®
No additional clinical trials were requested by the CHMP for submission of Vicinium marketing authorization application Anticipated submission of marketing authorization application in early 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical
May 4, 2020 Sesen Bio to Host Conference Call to Review First Quarter Financial Results and to Provide Operational Update Highlighting Positive Progress Towards Demonstrating Analytical Comparability
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 11,
Mar 16, 2020 Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results
Company on track to complete Vicinium ® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted
Feb 25, 2020 Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell , President and CEO, will host a conference call on Monday,
Feb 24, 2020 Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sesen Bio (Nasdaq: SESN ) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow , chief executive officer of Trevena, Inc., and
Jan 31, 2020 Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that it has granted non-statutory stock options to purchase an aggregate of 85,500
Top